LEIDEN, Netherlands, 12 November, 2026 – Ncardia, a leader in stem cell-based solutions for drug discovery and safety assessment, today announced the expansion of its neuroscience portfolio with six new human induced pluripotent stem cell (iPSC)-derived neuronal models under its Ncyte® brand.
The expanded portfolio includes:
- Dopaminergic neurons
- Motor neurons
- Excitatory neurons
- GABAergic neurons
- Sensory neurons
- Cholinergic neurons
These new models complement Ncardia’s existing glial cell options, broadening its human iPSC-based solutions for CNS drug discovery, disease modelling and neurotoxicity research.
The neuronal models provide pharmaceutical and biotechnology researchers with access to specialised human cell types without the need to establish differentiation workflows in-house.
“With this expansion, we’re strengthening our ability to support researchers working across different areas of neuroscience,” said Jeroen de Groot, CEO of Ncardia. “Our six new Ncyte® neurons give pharma and biotech teams ready-to-use, human-relevant cell types for CNS drug discovery, disease modelling and neurotoxicity studies, so they can spend their time on the science rather than on setting up differentiation protocols.”
For more information, visit www.ncardia.com.
About Ncardia
Ncardia is a research and development human iPSC technology company with facilities and offices located throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. The company’s goal is to enable biopharmaceutical companies to accelerate the discovery and development of new therapeutics in any drug modality, including drug, cell, and gene therapy, through the efficient integration of human iPSC technologies.
The Ncyte® neuronal models are intended for in vitro research use only.